Skip to main navigation
Skip to search
Skip to main content

UNT Health Home

Home
Research units
Profiles
Publications
Sponsored Projects
Core Facilities

Search by expertise, name or affiliation

Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: Avoiding a serious adverse drug interaction

Overview
Fingerprint

Cite this

Powered by Pure, Scopus & Elsevier Fingerprint Engine™

All content on this site: Copyright © 2026 UNT Health, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply

We use cookies to help provide and enhance our service and tailor content. By continuing you agree to the use of cookies

About web accessibility

Report vulnerability